Influenza, Human Clinical Trial
Official title:
Herd Immunity Communication and Influenza Vaccine Uptake
The aim of this study is to test the effectiveness of communicating the concept of herd immunity on actual influenza vaccine uptake using a randomized controlled trial.
The investigators run a large-scale randomized controlled trial (RCT) to understand
behavioural processes that guide decisions to vaccinate and test alternative strategies to
communicate the concept of herd immunity. The experiment varies the text of postal letters
send to individuals eligible for free influenza vaccines. The experiment is run in
collaboration with the municipal health authorities.
The investigators identify from the Population Register all individuals who are born in year
1953 or before and resided in the participating municipality on October 01, 2018. The
investigators will obtain the postal addresses of these individuals using the Population
Register and randomly assign individuals to treatment conditions that differ in the wording
of the information material and reception of a text message. Importantly, the extract from
the Population Register will also include an individual identifier (social security number)
that can be used to match the received type of letter (treatment) with the actual vaccination
decision recorded in the Care Register for Health Care to objectively evaluate the impact of
received information on vaccine uptake. The matching of postal addresses and vaccination data
will be conducted using pseudonymized identifiers. The pseudonymization of individual
identifiers will be performed separately for both datasets by professional data management
and data security staff of the National Institute for Health and Welfare. The investigators
conducting the data analysis will be able to access only pseudonymous data without a
possibility to directly identify individuals from the data set. The data will be stored
according to the data protection legislation and regulations of the National Institute for
Health and Welfare during the research project.
The investigators randomly assign individuals to treatment conditions that differ in the
wording of the letters. The authority's standard letter serves as the baseline condition
(T1). This letter is extended by communicating the concept of herd immunity and appealing to
pro-social preferences by highlighting the fact that vaccinations may effectively prevent
infections among people who are not able to vaccinate themselves (especially babies) (T2). To
summarize, this study includes a control treatment (T0, no letter) and two active treatment
arms with the following contents:
T1 (Mailing) - Standard letter T2 (Herd) - Herd immunity letter
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03275389 -
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
|
Phase 1 | |
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Completed |
NCT05981846 -
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
|
Phase 2 | |
| Completed |
NCT05044195 -
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
|
Phase 3 | |
| Completed |
NCT02914275 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
|
Phase 3 | |
| Completed |
NCT04590066 -
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
|
N/A | |
| Recruiting |
NCT03778203 -
Development of Childhood Anti-influenza Immunity
|
Phase 4 | |
| Completed |
NCT04527614 -
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
|
N/A | |
| Terminated |
NCT03658629 -
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
|
Phase 2 | |
| Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Completed |
NCT02867358 -
A Clinical Trial of KT07 Capsule in the U.S.A
|
Phase 2 | |
| Withdrawn |
NCT02883972 -
Childhood Influenza Immunisation Invitation Trial in Schools
|
N/A | |
| Completed |
NCT02998996 -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
|
Phase 1/Phase 2 | |
| Completed |
NCT02545543 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
|
Phase 3 | |
| Completed |
NCT02621164 -
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02212106 -
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
|
Phase 4 | |
| Completed |
NCT02243774 -
Mail Outreach To Increase Vaccination Acceptance Through Engagement
|
N/A | |
| Completed |
NCT02344134 -
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
|
Phase 3 |